European stocks rise as UK GDP jumps and Iran peace talks remain in focus

European stocks rise as UK GDP jumps and Iran peace talks remain in focus


A woman walks past mockups of Iranian missiles along Valiasr Square in Tehran on April 6, 2026.

Atta Kenare | Afp | Getty Images

LONDON — European stocks followed Asian markets higher on Thursday, as investors assess strong U.K. GDP data and Eurozone inflation data for March.

Markets also continue to keep a close eye on the progress of peace negotiations between the U.S. and Iran.

The pan-European Stoxx 600 index was seen 0.4% higher shortly after 1:15 p.m. in London, its sectors painting a mixed picture.

Miners and technology stocks led gains, while telecoms and airlines lagged the broader index.

The U.K.’s FTSE 100 index, France’s CAC 40 and Germany’s DAX each added 0.5% in early afternoon trade.

The British economy surpassed expectations with 0.5% growth in February, compared to forecasts of just 0.1%, according to official data published Thursday.

However, the outbreak of the Iran war at the end of February is set to derail U.K. growth prospects.

The war also had a significant impact on eurozone inflation data, which showed prices rose faster than expected in March at 2.6%, up from initial estimates of 2.5%.

In corporate news, shares in EasyJet fell on Thursday after it warned that the Iran war and higher fuel prices are weighing on customer bookings.

The airline said it took on roughly £25 million ($34 million) in additional fuel costs in the first half due to the U.S-Iran war. It expects airline costs to remain tied to volatile fuel prices over the coming months.

Shares dropped as much as 8.7%, before paring losses to last trade down 4.7%.

U.S. President Donald Trump said in an interview broadcast Wednesday that the conflict was “very close to over,” fueling market optimism that peace talks could resume and a resolution be found.

Bundesbank's Nagel: Iran war impact still significant for euro zone

The Associated Press, citing regional officials, reported Wednesday that the U.S. and Iran had an “in principle agreement” to extend their fragile two-week ceasefire in order to allow for more diplomacy.

But a senior U.S. official told CNBC that the U.S. “has not formally agreed to an extension of the ceasefire.”

“There is continued engagement between the U.S. and Iran to reach a deal,” added the official, who spoke on condition of anonymity to discuss the administration’s internal plans.

Overnight, Japan’s Nikkei 225 hit a record amid a broader rally in Asia markets, tracking gains on Wall Street on Wednesday as hopes of a U.S.-Iran deal grew. U.S. stock futures were little changed on Wednesday night after both the S&P 500 and Nasdaq Composite rose to fresh records during the regular session.

ESM’s Gramegna: Iran war already impacting economy
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source

OpenAI announces GPT-5.5, its latest artificial intelligence model
World

OpenAI announces GPT-5.5, its latest artificial intelligence model

OpenAI CEO Sam Altman during a media tour of a Stargate AI data center in Abilene, Texas, Sept. 23, 2025. Bloomberg | Bloomberg | Getty Images OpenAI on Thursday announced its latest artificial intelligence model, GPT-5.5, which the company says is better at coding, using computers and pursuing deeper research capabilities. The launch comes less […]

Read More
Software stocks plunge on ServiceNow, IBM results as AI fears escalate
World

Software stocks plunge on ServiceNow, IBM results as AI fears escalate

Signage outside the ServiceNow headquarters in Santa Clara, California, US, on Thursday, Sept. 4, 2025. David Paul Morris | Bloomberg | Getty Images Software stocks plummeted on Thursday as disappointing results from ServiceNow and IBM added to fears that artificial intelligence tools and services will disrupt their businesses. Shares of ServiceNow sank 17% Thursday, on […]

Read More
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
World

Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment

Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker.  First-quarter sales came in at 14.7 billion Swiss francs ($18.7 billion), down 5% year-on-year — but up 6% on a constant currency basis. […]

Read More